23andMe is a leading consumer genetics and research company founded in 2006. It provides direct-to-consumer genetic testing services, offering individuals insights into their ancestry, health predispositions, carrier status, and wellness traits based on their DNA. Beyond personal reports, 23andMe leverages its large, consented genetic database for research, aiming to make discoveries about human genetics and contribute to the development of new treatments. The company operates a therapeutics division focused on drug discovery informed by its genetic data.
Serves as the central hub for corporate strategy, executive leadership, primary research and development direction, marketing, legal, and administrative functions.
Located in a modern life sciences campus, likely featuring advanced laboratory spaces alongside collaborative office environments designed to foster innovation.
Characterized by a mission-driven focus on science, consumer empowerment, and genetic discovery. Often described as innovative and collaborative, though facing typical pressures of a publicly-traded tech/biotech company, including recent restructuring.
Its location in the Bay Area provides access to a rich talent pool in technology and biotechnology, crucial for its R&D and operational needs. It's the core decision-making center for the company's global operations.
While its physical offices are concentrated in California, 23andMe operates globally by offering its direct-to-consumer genetic testing kits to customers in numerous countries, including the United States, Canada, the United Kingdom, and various European nations. Its research platform utilizes consented, de-identified data from a diverse international customer base, contributing to genetic research with worldwide implications. Operational and corporate functions are primarily managed from the US headquarters.
349 Oyster Point Blvd
South San Francisco
CA
USA
Address: Potentially 223 N Mathilda Ave (previous HQ, may retain functions) or other facilities in the area; specific public details limited.
Accessing specialized tech talent, supporting R&D infrastructure, and potentially housing specific operational teams close to the main HQ.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, 23andMe' leadership includes:
23andMe has been backed by several prominent investors over the years, including:
Within the last year, 23andMe appointed a new permanent Chief Financial Officer following the departure of the previous CFO and an interim period. These changes occurred alongside broader company restructuring efforts aimed at refocusing priorities.
Discover the tools 23andMe uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
23andMe likely utilizes common corporate email structures. The most probable format involves the first initial followed by the last name.
[first_initial][last]@23andme.com
Format
awojcicki@23andme.com
Example
75%
Success rate
Fierce Biotech • February 1, 2024
23andMe confirmed another round of layoffs as part of a strategic shift to streamline its consumer business operations and prioritize accelerating its therapeutics pipeline, particularly focusing on its GSK-partnered programs....more
23andMe Blog / Press Release • December 6, 2023
The FDA granted 23andMe authorization for direct-to-consumer reports on pharmacogenetics, allowing the company to provide information on how an individual's genetics might influence their response to certain medications, starting with clopidogrel....more
23andMe Investor Relations • November 9, 2023
The company reported its financial results for the second quarter of fiscal year 2024, outlining revenue, losses, and progress in its consumer and therapeutics segments, alongside strategic updates including the appointment of Joe Selsavage as CFO....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including 23andMe, are just a search away.